Next-generation phenotypic antimicrobial susceptibility test platform: rapid resultsand comprehensive menus

该CRP SBIR提案的目标是为四个项目提供资金，以推进商业 Selux快速、全面、低成本、表型抗生素敏感性的准备 测试系统。Selux的下一代表型分析（NGP）平台独特地实现了快速 AST与全面的抗菌菜单>50药物在低成本从分离和 阳性血培养样本目标1和目标2侧重于对早期发展至关重要的降低成本项目， 客户采用。目标1包括支持多重口服检测的分析研究， 2是分析仪耗材包的DFM重新设计。目标3和4侧重于工作 为以后的客户采用。目标3是一项为期一年的基准研究， 将Selux NGP性能与传统AST系统和参考方法进行比较。通过 改进系统工作流程并对遗留系统的AST性能进行基准测试 这笔资金将帮助Selux NGP成为未来主导的AST平台。

The goal of this CRP SBIR proposal is to fund four projects to advance the commercial readiness of Selux’s rapid, comprehensive, low-cost, phenotypic antibiotic susceptibility test (AST) system. Selux’s next-generation phenotyping (NGP) platform uniquely enables rapid AST with comprehensive antimicrobial menus of >50 drugs at a low cost from isolates and positive blood culture samples. Aims 1 and 2 focus on cost reduction projects important for early customer adoption. Aim 1 comprises analytical studies to support multiplex oral panels and Aim 2 is a DFM redesign of the Analyzer consumable pack. Aims 3 and 4 focuses on work necessary for later customer adoption. Aim 3 is a yearlong benchmarking study that will compare Selux NGP performance against legacy AST systems and reference methods. By improving system workflows and benchmarking AST performance across legacy systems CRP funding will help position Selux NGP as the dominant AST platform of the future.